Atrium Therapeutics, Inc. (RNA): Insider Trading, Congress Trades & Research | Tormere
RNA
$8.68-0.46%
Atrium Therapeutics, Inc.
Market Cap
$149M
Live price × Finnhub shares (2026-09-22)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
—
Insufficient price history
P/E (TTM)
—
Price / TTM diluted EPS
P/S (TTM)
—
Mkt cap / TTM revenue
P/B
—
Mkt cap / shareholders' equity
EV/EBITDA (TTM)
—
EV / TTM EBITDA
Loading…
Financial Statements
USD thousands
Mar 2025
Mar 31, 2025
Jun 2025
Jun 30, 2025
Q1 FY2026
Mar 31, 2026
Q2 FY2026
Jun 30, 2026
Revenue
1,573
3,847
19,635
3,004
Research & development
6,937
13,293
16,657
15,343
Total operating expenses
9,025
16,711
36,915
25,622
Operating income
(7,452)
(12,864)
(17,280)
(22,618)
Net income
(7,449)
(12,879)
(16,633)
(20,186)
EPS (basic) ($)
(0.44)
(0.75)
(0.97)
(1.18)
EPS (diluted) ($)
(0.44)
(0.75)
(0.97)
(1.18)
Weighted avg. shares (basic)
17,106
17,106
17,106
17,106
Weighted avg. shares (diluted)
17,106
17,106
17,106
17,106
Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source
Informational purposes only, not investment advice.
Atrium Therapeutics, Inc. (RNA)
tormere.com/research/RNA · generated 2026-11-05
$8.68
-0.46%
General Information
Price$8.68
Change-0.46%
Market Cap$149M
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, monthly vs SPY)—
Signals
Insider Velocity—
Congress Trades (90d)—
Short Volume
47% of daily vol
Conviction Score—
Price Chart (1 Year)
Recent News
RNA stock: time to buy? — Cantech Letter · 2026-11-03
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History — Yahoo Finance · 2026-11-02
Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history — Yahoo Finance UK · 2026-11-02
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 — Yahoo · 2026-11-02
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy — Benzinga · 2026-11-02
Tormere — informational purposes only, not investment advice.
